ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Haahtela, T.
Right arrow Articles by Selroos, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haahtela, T.
Right arrow Articles by Selroos, O.
Eur Respir J 2006; 28:748-755
Copyright ©ERS Journals Ltd 2006

Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: a SOMA study

T. Haahtela1, K. Tamminen2, L. P. Malmberg1, O. Zetterström3, J. Karjalainen4, H. Ylä-Outinen5, T. Svahn2, T. Ekström6 and O. Selroos7

1 Skin and Allergy Hospital, Helsinki University Central Hospital, 2 AstraZeneca, Helsinki, 4 Pikonlinna Hospital, Tampere University Hospital, Tampere, 5 Paimio Hospital, Turku University Central Hospital, Turku, Finland., 3 Center for Allergy, University Hospital, Linköping, 6 AstraZeneca, Södertälje, and 7 SEMECO AB, Lund, Sweden.

CORRESPONDENCE: T. Haahtela, Skin and Allergy Hospital, Helsinki University Central Hospital, FIN-00290 Helsinki, Finland. Fax: 358 947186500. E-mail: tari.haahtela{at}hus.fi

Keywords: Asthma guidelines, budesonide, exhaled nitric oxide, formoterol, mild intermittent asthma, Turbuhaler®

Received: November 2, 2005
Accepted May 26, 2006

Patients with mild intermittent asthma sometimes show signs of inflammation, and guidelines suggesting bronchodilator therapy alone as needed may be questioned.

The current study compared as-needed use of a rapid-acting ß2-agonist with as-needed use of a ß2-agonist and corticosteroid combination as the only medication in asthma patients with intermittent symptoms. A total of 92 nonsmoking asthma patients (of 187 screened) using only an inhaled ß2-agonist as needed (28 males, 64 females; mean age 37 yrs; mean forced expiratory volume in one second (FEV1) 101% predicted, mean reversibility 6.5% pred and fractional exhaled nitric oxide (FeNO) ≥20 parts per billion (ppb)) were randomised to treatment with formoterol (Oxis® Turbuhaler®) 4.5 µg as needed (n = 47) or budesonide/formoterol (Symbicort® Turbuhaler®) 160/4.5 µg as needed (n = 45) in a double-blind, parallel-group 24-week study.

The primary variable of efficacy was change in FeNO. Baseline FeNO was 60 ppb and 59 ppb in the budesonide/formoterol and formoterol groups, respectively. Mean reductions in FeNO in the budesonide/formoterol and formoterol groups were 18.2 ppb and 2.8 ppb, respectively (95% confidence interval (CI) 7.5–23.5 ppb). The reduction in the budesonide/formoterol group occurred during the first 4 weeks of treatment and remained at this low level. Mean FEV1 increased by 1.8% pred normal value in the budesonide/formoterol group and decreased by 0.9% pred normal value in the formoterol group (95% CI -4.7– -0.7). In the budesonide/formoterol group, use of ≥4 inhalations·day-1 of study medication was seen on 21 treatment days compared with 74 in the formoterol group.

In conclusion, as-needed use of an inhaled corticosteroid together with a rapid-acting bronchodilator may be more beneficial than a ß2-agonist alone in patients with intermittent asthma and signs of airway inflammation. The long-term benefits are unknown.




This article has been cited by other articles:


Home page
Eur Respir JHome page
B. Dahlen, A-S. Lantz, E. Ihre, M. Skedinger, E. Henriksson, L. Jorgensen, T. Ekstrom, S-E. Dahlen, and K. Larsson
Effect of formoterol with or without budesonide in repeated low-dose allergen challenge
Eur. Respir. J., April 1, 2009; 33(4): 747 - 753.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
P. Rytila, L. Ghaly, S. Varghese, W. Chung, O. Selroos, T. Haahtela, and on behalf of the Airway Inflammation Study group
Treatment with inhaled steroids in patients with symptoms suggestive of asthma but with normal lung function
Eur. Respir. J., October 1, 2008; 32(4): 989 - 996.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
K. G. Lim and C. Mottram
The Use of Fraction of Exhaled Nitric Oxide in Pulmonary Practice
Chest, May 1, 2008; 133(5): 1232 - 1242.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the European Respiratory Society.